46 results about "Differentiation Antigens" patented technology

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse / human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse / human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and / or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.

Methods and compositions to elicit or enhance immunity in humans against self tumor antigens are disclosed. Such immunity is generated by immunization with homologous foreign proteins. Self tumor antigens include protein expression products of overexpressed human oncogenes, such as human HER-2 / neu protein, and organ-specific or tissue-specific differentiation antigens, such as PAP or PSA, associated with tumor cells.

The invention relates to a monoclonal antibody capable of recognizing a human leukocyte differentiation antigen CK8, a secretory cell strain, a preparation method thereof and application in immunodetection. According to the technical scheme, 340-365 amino acid sequences at the C tail end of CK8 protein are selected as antigen peptides, and the antigen peptides are coupled with KLH carrier protein to obtain the immunogen; the amino acid sequence of the antigen peptide is shown as SEQID1, a mouse is immunized, and the mouse hybridoma cell strain 14C2 capable of efficiently secreting the anti-CK8 protein monoclonal antibody and the anti-CK8 protein monoclonal antibody secreted by the cell strain are obtained through cell fusion, screening and subcloning. The antibody obtained by the scheme has high specificity and sensitivity, can specifically recognize cells expressing the CK8 protein, and is suitable for immunological detection, especially immunohistochemical detection.

The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.

The invention relates to the technical field of medical detection, in particular to a detection kit for minute residues of B-cell acute lymphocyte leukemia. The detection kit comprises anti CD10, CD19, CD20, CD34, CD38 and CD45 antibodies labeled by different fluoresceins. The detection kit comprises six monoclonal antibody combinations of leukocyte differentiation antigen, and a fluorescence labeling and flow cytometric detection technology is combined to realize that one-time flow cytometric detection can quickly and accurately identify the level and typing of abnormal cells of the minute residues of the B-cell acute lymphocyte leukemia, the obtained detection index can be used as an intermediate result to intuitively judge the prognosis conditions of B-cell acute lymphocyte leukemia patients, and thus important guiding significance is provided for the formulation of clinical treatment schemes for the leukemia patients.

The invention discloses a preparation method and application of a CAR-T cell based on PD-1 gene knock-out and base editing target CD133. The method comprises the steps that gene knocking out is conducted through a BE-Plus system while a plasmid vector expressing a leukocyte differentiation antigen CD133-CAR is guided into a T cell, and the obtained CAR-T cell can be applied to the preparation of anti-tumor drugs. The method has the advantages that the preparation technology is simple, and the method has higher application value in treating tumor cells.

Melanoma can be treated in a mammalian subject by administering to the subject an immunologically-effective amount of a xenogeneic melanoma-associated differentiation antigen. For example, genetic immunization with a plasmid containing a sequence encoding human gp75 has been shown to be effective in treatment of dogs with melanoma.

The invention relates to a double-antibody combined fluorescence detection kit for liver cancer resection postoperative prognosis. The double-antibody combined fluorescence detection kit for liver cancer resection postoperative prognosis comprises a first antibody and a second antibody, wherein the first antibody is selected from the antibody combination of the following protein molecular markers:CD68 (cell differentiation antigen 68) and PD-L1 (procedural death ligand 1). The kit uses double-antibody combination indexes; the expression mode of the PD-L1 in tissues can be precisely reflected,so that the prognosis of a patient is better evaluated; the kit can help doctors to select the proper treatment user groups and modes, so that the powerful support is provided for effective diagnosisand treatment.

A polypeptide has the antibody binding activity of the 46 Kdalton HMFG differentiation antigen and / or homology to at least one of the light chains of clotting factors V and VIII and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof in vivo and in vitro methods for therapy vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and / or polypeptides of the invention.

The invention concerns an improvement in the art of inserting and expressing foreign gene into eukaryotic cells. The invention particularly concerns methods and compositions whereby viral vectors can be used to insert and express foreign genes into specifically cells having particular differentiation antigens. A method of determining which differentiation antigens can be used is taught. The invention encompasses complexes of viral particles and adapters that cause the binding and internalization of the vector particles such that a gene of interest in the particle is expressed.

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

The invention discloses an IL-2 and MART-1 dual-gene co-expression recombinant vector, which is sequentially linked with an IL-2 gene, an IRES sequence and an MART-1 gene in a vector transcription direction, or is sequentially linked with an MART-1 gene, an IRES sequence and an IL-2 gene in a vector transcription direction, wherein nucleotide sequence of the IL-2 gene is represented in SEQ ID NO: 1 in a sequence list, nucleotide sequence of the MART-1 gene is represented in SEQ ID NO: 2 in the sequence list, and nucleotide sequence of the IRES sequence is represented in SEQ ID NO: 3 in the sequence list. The dual-gene co-expression recombinant vector, which links the IL-2 gene and the MART-1 gene through the IRES sequence, can simultaneously express a human melanin differentiation antigen and interleukin-2; the recombinant vector, in immunogene therapy of melanin, not only can develop an immune regulating function of a cell factor but also can generate a specific anti-tumor effect aiming at the melanin.

The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer / testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.

The invention discloses a separate culture method for human amniotic mesenchymal stem cells, and belongs to the technical field of biology. The separate culture method comprises the following steps: (I) cell separation; (II) cell culture: inoculating a single separated human amniotic karyocyte into a plastic culture bottle of 75cm<2>, culturing in a 5 percent CO2 incubator at the temperature 37 DEG C, wherein a culture solution is a culture medium special for the human amniotic mesenchymal stem cell; replacing the culture solution 24 hours later, discarding non-adherent cells, and replacing the culture solution every 2 to 3 days; fusing the cells after the human amniotic mesenchymal stem cells grow to 70 to 80 percent, digesting with pancreatin, and performing passage; performing passage once in the culture medium special for the human amniotic mesenchymal stem cells every 2 to 3 days at the temperature of 37 DEG C and in 5 percent CO2. The obtained human amniotic mesenchymal stem cells express by the following three kinds of cell membrane molecules, namely, a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90 and a human leukocyte differentiation antigen CD105, and do not express a human leukocyte differentiation antigen CD45 and a human leucocyte antigen HLA-DR.

The invention provides a group of antitumor T lymphocytes. The group of antitumor T lymphocytes are used for representing the following five types of lymphocyte membrane molecules to a certain extent: human leukocyte differentiation antigens CD3, human leukocyte differentiation antigens CD4, human leukocyte differentiation antigens CD8, human Alpha Beta T cell receptors and human Gamma Delta T cell receptors, thereby inhibiting the proliferation of breast cancers and hepatoma cell lines, inducing the apoptosis of cancer cells as well as inhibiting the growth of the in-vivo tumors of tumor-bearing mice suffering from the hepatoma and the breast cancers. If the antitumor T lymphocytes provided by the invention are matched with the traditional surgery, chemotherapy and radiation therapy, a small quantity of residues and diffused tumor cells are removed and killed in a biological therapy mode after a large quantity of tumor cells are removed by the conventional therapy method, thereby improving and consolidating the tumor therapy and reducing the tumor relapse.

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

The invention relates to the technical field of medication. The tumour is always cured by operation, irradiation and chemical medication, and the induction differentiation therapy of malignant tumour becomes the research hotpot and frontier field of cancer biology and tumor therapeutics at present. The invention aims at providing a now application of tunicamycin which is the application in preparing a tumour cell reversing drug. The concentration of low-dosage tunicamycin adopted by the invention is 0.1-0.5mug / ml. After a myeloma cell line is treated, myeloma cell strain is differentiated in state, which is shown as cells are transited into mature plasma cell state; cell differentiation antigen CD49e is raised; and excreted immune globulin light chains are also increased. The invention has the advantages of low drug dosage of the tunicamycin, exact effect, less influence on normal cell and benefit for improving the living state of tumour patients.

The invention provides an antibody detection kit. The antibody detection kit comprises an antibody of a programmed death receptor 1 and antibodies of at least three cluster differentiation antigens. The antibody of the programmed death receptor 1 and the antibody of each cluster differentiation antigen carry different fluoresceins, the at least three cluster differentiation antigens comprise a mature T cell surface marker, an auxiliary T cell surface marker and a cytotoxic T cell surface marker, and can be used for rapidly investigating the expression condition of PD-1 protein, and the staining index of fluorescein carried by the antibody of the programmed death receptor 1 is higher than that of fluorescein carried by the antibody of each cluster differentiation antigen, so that the expression condition of the PD-1 protein can be accurately investigated. The invention also provides application of the antibody detection kit in immunoassay.

The invention discloses an IL-2 and MART-1 dual-gene co-expression recombinant vector, which is sequentially linked with an IL-2 gene, an IRES sequence and an MART-1 gene in a vector transcription direction, or is sequentially linked with an MART-1 gene, an IRES sequence and an IL-2 gene in a vector transcription direction, wherein nucleotide sequence of the IL-2 gene is represented in SEQ ID NO: 1 in a sequence list, nucleotide sequence of the MART-1 gene is represented in SEQ ID NO: 2 in the sequence list, and nucleotide sequence of the IRES sequence is represented in SEQ ID NO: 3 in the sequence list. The dual-gene co-expression recombinant vector, which links the IL-2 gene and the MART-1 gene through the IRES sequence, can simultaneously express a human melanin differentiation antigen and interleukin-2; the recombinant vector, in immunogene therapy of melanin, not only can develop an immune regulating function of a cell factor but also can generate a specific anti-tumor effect aiming at the melanin.

Tolerance of the immune system for endogenous TRP2 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed TRP2 antigen. For example, mouse TRP2, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against TRP2 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing TRP2, such as melanoma.

The invention discloses a CD29<+> human umbilical cord-derived mesenchymal stem cell and an application thereof in preparation of a bone tissue engineering seed cell used for treating bone injury. The CD29<+> human umbilical cord-derived mesenchymal stem cell expresses the following four mesenchymal stem cell membrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. The CD29<+> human umbilical cord-derived mesenchymal stem cell disclosed by the invention can be converted into a bone cell in a mouse to participate in fracture healing, has low immunogenicity and can be taken as a cell source of tissue-engineered bone, then the traditional surgical therapy scheme is combined, and a good therapeutic effect can be achieved, so that the CD29<+> human umbilical cord-derived mesenchymal stem cell disclosed by the invention has a broad application prospect.

The invention discloses a GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) and MART-1 (Melanoma Antigen Recognized By T-Cells 1) dual-gene co-expression recombinant vector. The GM-CSF and MART-1 dual-gene co-expression recombinant vector is characterized that a GM-CSF gene, an IRES (Internal Ribosome Entry Sequence) and an MART-1 gene are connected in sequence along the vector transcription direction, or the MART-1 gene, IRES and GM-CSF gene are connected in sequence along the vector transcription direction; a nucleotide sequence of the GM-CSF gene is as shown in SEQ ID NO:1 in a sequence table; the nucleotide sequence of the MART-1 gene is as shown in SEQ ID NO:2 in the sequence table; the nucleotide sequence of the IRES is as shown in SEQ ID NO:3 in the sequence table. According to the dual-gene co-expression recombinant vector, the IRES sequence is utilized for connecting the GM-CSF gene with the MART-1 gene, and thus human melanoma differentiation antigen and the granulocyte-macrophage colony-stimulating factor can be expressed in the same vector at the same time; the recombinant vector can be applied to immunogene therapy of melanoma, enables the immune regulation effect of cytokines to be played, and can also produce specific anti-tumor effect for malignant melanoma in a targeting way.

Tolerance of the immune system for endogenous gp100 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed gp100 antigen. For example, mouse gp100, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against gp100 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing gp100, such as melanoma.

The invention discloses a CD29<+> human umbilical cord source mesenchymal stem cell and use thereof in the preparation of a drug for treating skeletal muscle atrophy in high-sugar and high-fat environments. The CD29<+> human umbilical cord source mesenchymal stem cell represents the following mesenchymal stem cell cytomembrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. According to the CD29<+> human umbilical cord source mesenchymalstem cell, the hyperlipidemia and hyperglycemia of a db<- / -> mouse can be obviously improved, muscle fiber cross sections of soleus and gastrocnemius muscle of the db<- / -> mouse can be increased, andthe contents and cell number of each myotube are increased, so that the symptoms of the skeletal muscle atrophy of the db<- / -> mouse are improved. According to the CD29<+> human umbilical cord sourcemesenchymal stem cell, the theoretical foundation and experiment basis are laid for the subsequent research and development of the drug for treating skeletal muscle atrophy in the high-sugar and high-fat environments, and the CD29<+> human umbilical cord source mesenchymal stem cell has wide application prospects.